Key Takeaways AMCR will report Q2 FY26 results on Feb. 3, with revenues seen at $5.55B and earnings of 83 cents per share.AMCR's outlook reflects a major revenue boost from the Berry Global merger, offsetting volume pressure.AMCR's segments face volume declines, cushioned by price/mix gains, currency benefits and acquisitions.Amcor Plc (AMCR) is scheduled to report second-quarter fiscal 2026 results on Feb. 3, after the closing bell.The Zacks Consensus Estimate for AMCR’s fiscal second-quarter revenues is p ...

Core Viewpoint - AbbVie is expected to report fourth-quarter and full-year 2025 earnings on February 4, with sales projected at $16.36 billion and earnings per share (EPS) at $2.66, although EPS estimates for 2025 and 2026 have declined recently [2][6]. Earnings Performance - AbbVie has consistently exceeded earnings expectations in the past four quarters, with an average earnings surprise of 3.05%, including a 5.08% surprise in the last quarter [4][6]. Revenue Drivers - The anticipated revenue growth for AbbVie in Q4 2025 is primarily driven by increased sales of newer immunology drugs, Skyrizi and Rinvoq, as sales of the flagship drug Humira continue to decline due to biosimilar competition [9][10]. - The Zacks Consensus Estimate for Skyrizi sales is $4.91 billion, while Rinvoq is estimated at $2.39 billion [9]. Sales Estimates - Humira's sales are projected at $949 million, reflecting ongoing erosion from biosimilars, while Imbruvica sales are expected to decline to $715 million due to competition [10]. - Sales for Roche-partnered Venclexta are estimated to rise to $725 million, driven by strong demand [11]. - Neuroscience product sales are expected to reach approximately $3.00 billion, supported by strong performances from Botox Therapeutic, Vraylar, and new migraine drugs [12]. - Aesthetics product sales are projected at $1.28 billion, showing signs of recovery from previous sluggishness [13]. Valuation and Market Position - AbbVie shares are currently trading at a P/E ratio of 15.38, below the industry average of 18.42, indicating a discount relative to peers [17]. - Despite underperforming the industry over the past year, AbbVie is expected to achieve robust revenue growth driven by its newer drug launches [19]. Future Outlook - AbbVie anticipates a high single-digit revenue compound annual growth rate (CAGR) through 2029, supported by the successful launches of Skyrizi and Rinvoq [19]. - The company continues to invest in its pipeline through strategic collaborations, including a recent licensing deal with RemeGen for a bispecific antibody candidate [21]. - A favorable valuation and strong earnings growth expectations provide a compelling case for long-term investment in AbbVie stock [22].

Core Insights - Symbotic Inc. (SYM) is expected to report first-quarter fiscal 2026 results on February 4, with revenue estimates at $622.31 million, reflecting a 27.9% year-over-year growth and earnings estimated at 8 cents per share, indicating a 366.7% increase from the previous year [1][7]. Revenue and Earnings Estimates - The Zacks Consensus Estimate for SYM's revenues in Q1 is $622.31 million, with a projected growth rate of 25-29% based on backlog conversion [1][5]. - The earnings estimate for Q1 remains stable at 8 cents per share over the past 60 days, with no revisions [2][3]. Backlog and Growth Drivers - SYM reported a backlog of $22.5 billion in Q4 of fiscal 2025, which is anticipated to drive revenue growth in Q1 fiscal 2026 [5]. - The company projects adjusted EBITDA between $49 million and $53 million for the first quarter [5]. Cost and Margin Concerns - High operating costs, particularly in research and development and selling, general, and administrative expenses, are expected to negatively impact bottom-line performance [6][15]. - The company's significant investments to maintain technological advantages have contributed to increased costs [6]. Stock Performance and Valuation - SYM's shares have declined over 33% in the past three months, underperforming its industry and peers [7][8]. - The company is considered relatively overvalued, trading at a high forward 12-month price-to-sales ratio compared to industry averages and competitors [11]. Customer Dependency - SYM's reliance on Walmart, its largest customer, raises concerns, as this partnership constitutes a significant portion of its revenues [15]. - The acquisition of Walmart's advanced systems and robotics business in January 2025 has further solidified this dependency [15].

Core Viewpoint - Amkor Technology (AMKR) is anticipated to report flat earnings of $0.43 per share for the quarter ended December 2025, with revenues expected to rise by 12.1% to $1.83 billion compared to the previous year [3][12]. Earnings Expectations - The upcoming earnings report is scheduled for February 9, and the stock may experience upward movement if earnings exceed expectations, while a miss could lead to a decline [2]. - The consensus EPS estimate has been revised 19.3% higher in the last 30 days, indicating a positive reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate for Amkor Technology aligns with the consensus estimate, resulting in an Earnings ESP of 0% [12]. - Despite a Zacks Rank of 1 (Strong Buy), the lack of a positive Earnings ESP makes it challenging to predict an earnings beat [12]. Historical Performance - In the last reported quarter, Amkor Technology exceeded the consensus EPS estimate of $0.42 by delivering earnings of $0.51, resulting in a surprise of +21.43% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates three times [14]. Industry Context - Alpha and Omega Semiconductor (AOSL), another player in the semiconductor industry, is expected to report a loss of $0.08 per share, reflecting a significant year-over-year decline of -188.9% [18]. - AOSL's revenues are projected to decrease by 7.6% to $160 million, but it has an Earnings ESP of +62.50%, suggesting a likely earnings beat [19][20].

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for PowerFleet (AIOT) due to higher revenues, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - PowerFleet is expected to report a quarterly loss of $0.00 per share, reflecting a year-over-year change of +100% [3]. - Revenues are projected to be $111.73 million, representing a 5% increase from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised 33.33% higher in the last 30 days, indicating a positive reassessment by analysts [4]. - The Most Accurate Estimate for PowerFleet is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +350.00% [12]. Earnings Surprise Prediction - A positive Earnings ESP is a strong indicator of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10]. - PowerFleet currently holds a Zacks Rank of 3, suggesting a likelihood of beating the consensus EPS estimate [12]. Historical Performance - PowerFleet has not been able to beat consensus EPS estimates in the last four quarters, with a previous surprise of -60% [13][14]. Industry Context - Another company in the Zacks Internet - Software industry, Reddit Inc. (RDDT), is expected to post earnings of $0.96 per share, indicating a year-over-year change of +166.7% [18]. - Reddit Inc.'s revenues are expected to be $667.58 million, up 56.1% from the previous year, but it has a negative Earnings ESP of -14.49% and a Zacks Rank of 4 [19][20].

Wall Street expects a year-over-year decline in earnings on higher revenues when Cincinnati Financial (CINF) reports results for the quarter ended December 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Fe ...

Corebridge Financial Overview - Corebridge Financial (CRBG) is expected to report a year-over-year decline in earnings of 9.8%, with an estimated EPS of $1.11 for the quarter ended December 2025, while revenues are projected to increase by 0.9% to $5.06 billion [3][12] Earnings Expectations and Market Reaction - The stock price may rise if the actual earnings exceed expectations in the upcoming report scheduled for February 9, while a miss could lead to a decline in stock price [2][15] - The consensus EPS estimate has been revised down by 0.21% over the last 30 days, indicating a reassessment by analysts [4] Earnings Surprise Prediction - The Most Accurate Estimate for Corebridge is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +0.57%, although the stock has a Zacks Rank of 4, complicating predictions of an earnings beat [12][20] - A positive Earnings ESP is generally a strong predictor of an earnings beat, especially when combined with a favorable Zacks Rank [10] Historical Performance - In the last reported quarter, Corebridge was expected to post earnings of $1.08 per share but only achieved $0.96, resulting in a surprise of -11.11% [13] - Over the past four quarters, Corebridge has beaten consensus EPS estimates three times [14] Industry Comparison - MetLife (MET), another player in the Zacks Insurance - Multi line industry, is expected to report earnings of $2.36 per share, reflecting a year-over-year increase of 13.5%, with revenues projected to rise by 29.6% to $25.57 billion [18][19]

Core Viewpoint - The market anticipates a year-over-year decline in earnings for CNA Financial despite an increase in revenues, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - CNA Financial is expected to report quarterly earnings of $1.20 per share, reflecting a -4% change year-over-year, while revenues are projected to be $3.5 billion, up 5% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analysts' assessments [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates a positive Earnings ESP of +11.67% for CNA Financial, suggesting analysts have recently become more optimistic about the company's earnings prospects [12]. Historical Performance - In the last reported quarter, CNA Financial exceeded the expected earnings of $1.25 per share by delivering $1.50, resulting in a surprise of +20.00% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates three times [14]. Investment Considerations - While a positive earnings surprise can influence stock movement, other factors may also play a significant role in determining stock performance [15]. - The combination of a positive Earnings ESP and a Zacks Rank of 3 indicates a likelihood of beating the consensus EPS estimate [12][10].

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for iBio, Inc. despite lower revenues, with actual results being crucial for stock price movement [1] Earnings Expectations - iBio is expected to report a quarterly loss of $0.08 per share, reflecting a year-over-year change of +83.3% [3] - Revenues are projected to be $0.1 million, down 50% from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has been revised 3.45% higher in the last 30 days, indicating a reassessment by analysts [4] - A positive Earnings ESP of +27.27% suggests analysts have become more optimistic about iBio's earnings prospects [12] Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10] - iBio currently holds a Zacks Rank of 3, which, along with the positive Earnings ESP, suggests a likelihood of beating the consensus EPS estimate [12] Historical Performance - In the last reported quarter, iBio was expected to post a loss of $0.07 per share but actually reported a loss of -$0.11, resulting in a surprise of -57.14% [13] - Over the past four quarters, iBio has only beaten consensus EPS estimates once [14] Industry Comparison - Bristol Myers Squibb is expected to report an EPS of $1.15 for the same quarter, indicating a year-over-year change of -31.1% [18] - Revenues for Bristol Myers are expected to be $12.25 billion, down 0.7% from the previous year [18] - The consensus EPS estimate for Bristol Myers has been revised down by 3.9% in the last 30 days, and it currently has an Earnings ESP of 0.00% [19][20]

Core Insights - Phillips 66 (PSX) is scheduled to report its fourth-quarter 2025 results on February 4, 2026, with earnings per share (EPS) estimated at $2.11, indicating a significant improvement from the previous year [1] - The consensus estimate for fourth-quarter revenues is projected at $30.2 billion, reflecting an 11.3% decline compared to the same period last year [1][7] - PSX has exceeded earnings estimates in three of the last four quarters, with an average surprise of 18.3% [2] Earnings Predictions - The model predicts an earnings beat for PSX, supported by a positive Earnings ESP of +0.88% and a Zacks Rank of 3 (Hold) [4] - The average WTI spot prices for the last quarter of 2025 were $60.89, $60.06, and $57.97 per barrel for October, November, and December, respectively, compared to higher prices in the same months of 2024 [6] Price Performance and Valuation - PSX's stock has increased by 21.8% over the past year, closely aligning with the industry average of 21.9% [8] - The current trailing 12-month EV/EBITDA ratio for PSX is 14.68, indicating it is trading at a premium compared to the industry average of 4.77 [11] Industry Context - The EIA projects the average WTI price for 2026 to be $52.21 per barrel, down from $65.40 per barrel in 2025, suggesting a favorable environment for refining companies like PSX [15] - Valero Energy reported fourth-quarter 2025 adjusted earnings of $3.82 per share, surpassing estimates, while Marathon Petroleum Corp. (MPC) is set to report on February 3, with a current Earnings ESP of 0.00% and a Zacks Rank of 4 (Sell) [16]